Cancer vaccines market predicted to be worth $24 billion in 2033

3 March 2023
oncology_cancer_large

The global cancer vaccines market is expected to garner a market value of $9 billion in 2023 and is expected to accumulate a market value of $24.22 billion by registering a compound annual growth rate (CAGR) of 12% in the forecast period 2023 to 2033.

The market for cancer vaccines registered a CAGR of 9% in the historical period 2018 to 2022, according to a report from Future Market Insights.

The cancer vaccines market is expected to experience significant growth in the coming years, driven by several factors. According to the World Health Organization (WHO), cancer is the second leading cause of death worldwide, responsible for an estimated 9.6 million deaths in 2018. The most common types of cancer worldwide include lung, breast, colorectal, prostate, stomach, and liver cancer.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical